flutemetamol F-18 (vizamyl) Report issue

Small molecule Imaging Approved FDA
AACT ChEMBL DrugBank Drug Central Drugs@FDA KEGG MeSH PubChem

Active Ingredient History

NOW
  • Now
Flutemetamol F 18 is a radioactive molecular agent that is intended for use with PET imaging of the brain in adults being evaluated for Alzheimer's disease (AD) and dementia. Flutemetamol F 18 consists of flutemetamol, a thioflavin derivative of Pittsburgh compound B (PiB) labeled with the radioisotope fluorine F18 and it selectively binds to cerebral fibrillar beta-amyloid, a peptide involved in Alzheimer's disease.   NCATS

Chemistry

  • SMILES: CNc1ccc(cc1F)c2nc3ccc(O)cc3s2
  • InChIKey: VVECGOCJFKTUAX-UHFFFAOYSA-N
  • Mol. Mass: 274.32
  • ALogP: 3.85
  • ChEMBL Molecules:
    flutemetamol  
    flutemetamol f 18  
More Chemistry

Pharmacology

  • Mechanism of Action:
  • Multi-specific: Missing data
  • Imaging: 18-fluorine
  • Black Box: No
  • Availability: Prescription Only
  • Delivery Methods: Parenteral
  • Pro Drug: No

Drug Pricing (per unit)

United States

$65274.4600
More Pricing Detail

Note: This drug pricing data is preliminary, incomplete, and may contain errors.

Alternative names

[18f]ah110690 | 18f flutametamol | (18f)flutemetamol | [18f]-flutemetamol | 18f flutemetamol | 18f-flutemetamol | [18f]-flutemetamol f18 | 2-[3-(18f)fluoro-4-(methylamino)phenyl]-1,3-benzothiazol-6-ol | [3h]-flutemetamol | ah110690 | flutemetamol | flutemetamol (18f) | flutemetamol f18 | flutemetamol f 18 | flutemetamol f-18 | flutemetamol f 18 injection | vizamyl

Organizations (17)

Research & Development (17)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Marketing (1)

Organization Org Type FDA approvals Clinical Trials involvement Org ID Force Sort

Indications (12)

Approved Indications (1)


 

Alzheimer Disease (approved 2013)

Experimental Indications - Clinical Trial Phases 1-4 (12)


 

Alzheimer Disease (Phase 3)

Amyloidosis (Early Phase 1)

Atherosclerosis (Phase 2/Phase 3)

Brain Diseases (Phase 3)

Cardiomyopathies (Phase 1)

Carotid Stenosis (Phase 2)

Cognition Disorders (Phase 2)

Cognitive Dysfunction (Phase 3)

Dementia (Phase 3)

Healthy Volunteers (Phase 3)

Hydrocephalus, Normal Pressure (Phase 3)

Inflammation (Phase 2)

Overview

  • Highest Phase: Phase 3
  • # of Trials: 17
  • # of Trial Organizations: 17

Trials by Phase

Trial Phase Start Date Organizations Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue